European Commission Grants Orphan Drug Designation to JR-446 for Treatment of Mucopolysaccharidosis Type IIIB

Strategic Insights -

The European Commission has granted orphan drug designation to JR-446, an investigational treatment for mucopolysaccharidosis type IIIB (MPS IIIB or Sanfilippo syndrome type B), following the recent designation by the U.S. Food and Drug Administration (FDA). This marks a significant step forward in the development of JR-446, which has shown promising non-clinical results in addressing the central nervous system symptoms of this challenging disorder. The orphan drug designation is expected to provide various incentives to encourage the development of JR-446 in the European Union.

Key Takeaways:

  • JR-446, developed using JCR's proprietary J-Brain Cargo([R]) technology, has been granted orphan drug designation by the European Commission for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB or Sanfilippo syndrome type B).
  • The orphan drug designation will provide various incentives, including market exclusivity for 10 years in the EU, scientific guidance, and fee reductions, to encourage the development of JR-446 in the European Union.
  • JR-446 is currently being studied in a Phase I/II trial in Japan under a collaboration agreement between MEDIPAL and JCR.
  • MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system (CNS) symptoms, and there are currently no approved treatments available for this condition.
  • MEDIPAL will commercialize JR-446 for MPS IIIB outside of Japan under a licensing agreement with JCR, signed in September 2023.
  • JCR's proprietary J-Brain Cargo([R]) technology has shown promising non-clinical results in addressing the CNS symptoms of MPS IIIB.

Statistics:

  • The estimated number of individuals afflicted with MPS IIIB worldwide is 500 to 1,000 people.
  • The orphan drug designation will provide market exclusivity for 10 years in the European Union.
  • The Phase I/II trial for JR-446 is currently ongoing in Japan, with plans for future clinical development in other regions.
  • MEDIPAL will support JCR in the clinical development of JR-446 in Japan, including disease awareness, clinical trial advancement, and distribution of investigational drugs.

Sources:

  • 1. U.S. FDA Press release on orphan drug designation for JR-446 for Mucopolysaccharidosis Type IIIB
  • 2. JCR Pharmaceuticals Co., Ltd. own investigations and data from the Ministry of Health, Labour and Welfare's public research
  • 3. MEDIPAL HOLDINGS CORPORATION Press release on licensing agreement for JR-446 between MEDIPAL and JCR (September 28, 2023)